Do you think SpaceX $SPCX will outperform the S&P 500 $SPY over the next 5 years?
SpaceX is one of the most anticipated IPOs in recent history. Its booming business across the space industry has created tremendous hype, but hype doesn't always translate to outperformance. Do you think SpaceX will outperform the S&P 500 over the next five years?
$RKLB The Space ETF/ SpaceX rally engulfed the Dilution news.
Pretty good timing, to be honest. If management timed that on purpose with expectation of the rally, then A+
$EOSE First time in a while I’ve seen a earnings good enough that a 30% pump is justified instead of it just being a meme run.
Killed it both earnings and guidance.
$NBIS no one panic of they offer a secondary in the next few days. It makes sense strategically to fund growth.
I rode Tesla from 2018 until last year and watched them keep raising money every time there was a huge move up.
$HIMS i was expecting bigger pullback, but unless they destroy the pattern it looks like it consolidated and may want to curl up to push higher tomorrow. lets see
$SOUN during our 2 parabolic runs to $24.98 & $22.17 in the past 2 years there were some hiccups as we climb those mountains. Just stand by. We'll be at $20+ soon, it's just a hiccup day. Just Drink some water.
$SNAP will probably see a drop at open from people who bought at $4 selling but then we will take off. Dropped from $9 with no bad news. Could easily get in the $8-9 range before earnings then $10-12 with positive earnings.
$MAAS success isn't just about being bullish. It requires integration milestones, customer wins, and clear AI revenue growth. What key milestones are you watching for?
$MAAS is shifting from operator to full-stack AI leader. This positioning leap is massive, but the market will need proof before a re-rating occurs. What do you think of this pivot?
Just use the block button on bots like $GRRR mentions. Engaging or reposting only spreads their content. Have a wonderful day! Do you find blocking tools helpful?
I suspect big pharma is pressuring the FDA against $IBRX and Anktiva. Other nations are approving it for more cancers while the FDA resists. Do you think the FDA is biased?
$MAAS is hitting a small but useful milestone. It is a meaningful step for the business growth of $SMCI, $ASTS, and $NVDA. Are you tracking this progress?